301331 恩威医药
已收盘 11-02 15:00:00
资讯
新帖
简况
股市必读：恩威医药新发布《2026年三季度报告》
证券之星 · 10-27
股市必读：恩威医药新发布《2026年三季度报告》
恩威医药(301331)9月30日股东户数0.78万户，较上期增加16.5%
证券之星 · 10-25
恩威医药(301331)9月30日股东户数0.78万户，较上期增加16.5%
图解恩威医药三季报：第三季度单季净利润同比增长463.79%
证券之星 · 10-25
图解恩威医药三季报：第三季度单季净利润同比增长463.79%
恩威医药（301331）披露控股股东一致行动人部分股份质押公告，10月14日股价下跌2.32%
证券之星 · 10-14
恩威医药（301331）披露控股股东一致行动人部分股份质押公告，10月14日股价下跌2.32%
股市必读：恩威医药中报 - 第二季度单季净利润同比下降84.04%
证券之星 · 08-28
股市必读：恩威医药中报 - 第二季度单季净利润同比下降84.04%
图解恩威医药中报：第二季度单季净利润同比下降84.04%
证券之星 · 08-27
图解恩威医药中报：第二季度单季净利润同比下降84.04%
恩威医药（301331）披露2026年半年度募集资金存放与使用情况的专项报告，8月26日股价下跌1.25%
证券之星 · 08-26
恩威医药（301331）披露2026年半年度募集资金存放与使用情况的专项报告，8月26日股价下跌1.25%
恩威医药（301331）披露与专业投资机构共同投资设立基金进展公告，7月30日股价下跌4.02%
证券之星 · 07-30
恩威医药（301331）披露与专业投资机构共同投资设立基金进展公告，7月30日股价下跌4.02%
恩威医药（301331）披露控股股东部分股份解除司法冻结公告，7月17日股价下跌7.51%
证券之星 · 07-17
恩威医药（301331）披露控股股东部分股份解除司法冻结公告，7月17日股价下跌7.51%
恩威医药：公司出资2000万元认购嘉兴磐霖嘉颐份额
证券之星 · 07-15
恩威医药：公司出资2000万元认购嘉兴磐霖嘉颐份额
恩威医药（301331）披露控股股东及持股5%以上股东部分股份质押公告，7月14日股价上涨2.94%
证券之星 · 07-14
恩威医药（301331）披露控股股东及持股5%以上股东部分股份质押公告，7月14日股价上涨2.94%
恩威医药（301331）披露与专业投资机构共同投资设立基金进展公告，7月6日股价下跌2.97%
证券之星 · 07-06
恩威医药（301331）披露与专业投资机构共同投资设立基金进展公告，7月6日股价下跌2.97%
恩威医药（301331）披露控股股东部分股份解除质押公告，6月29日股价上涨4.02%
证券之星 · 06-29
恩威医药（301331）披露控股股东部分股份解除质押公告，6月29日股价上涨4.02%
恩威医药（301331）披露控股股东及持股5%以上股东部分股份解除质押公告，6月1日股价上涨1.75%
证券之星 · 06-01
恩威医药（301331）披露控股股东及持股5%以上股东部分股份解除质押公告，6月1日股价上涨1.75%
恩威医药：公司以2000万元出资认购嘉兴磐霖嘉颐创业投资合伙企业份额
证券之星 · 05-27
恩威医药：公司以2000万元出资认购嘉兴磐霖嘉颐创业投资合伙企业份额
恩威医药（301331）披露2025年度持续督导定期现场检查报告，5月21日股价下跌3.13%
证券之星 · 05-21
恩威医药（301331）披露2025年度持续督导定期现场检查报告，5月21日股价下跌3.13%
恩威医药（301331）披露2025年年度股东会决议公告，5月19日股价上涨0.68%
证券之星 · 05-19
恩威医药（301331）披露2025年年度股东会决议公告，5月19日股价上涨0.68%
恩威医药（301331）披露首次公开发行股票持续督导保荐总结报告书，5月15日股价下跌0.68%
证券之星 · 05-15
恩威医药（301331）披露首次公开发行股票持续督导保荐总结报告书，5月15日股价下跌0.68%
恩威医药：公司一贯重视市值管理工作
证券之星 · 05-14
恩威医药：公司一贯重视市值管理工作
恩威医药：2025-2027三年发展及增长计划，总目标是“三年番一翻”
证券之星 · 05-13
恩威医药：2025-2027三年发展及增长计划，总目标是“三年番一翻”
暂无数据
公司概况
公司名称：
恩威医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是妇科外用洗液“洁尔阴洗液”、软膏、栓剂、胶囊剂、泡腾片。
发行价格：
29.80
{"stockData":{"symbol":"301331","market":"SZ","secType":"STK","nameCN":"恩威医药","latestPrice":23.6,"timestamp":1793603025000,"preClose":21.15,"halted":0,"volume":9319017,"delay":0,"changeRate":0.1158,"floatShares":102000000,"shares":103000000,"eps":0.3673,"marketStatus":"已收盘","change":2.45,"latestTime":"11-02 15:00:00","open":21.3,"high":24.9,"low":20.58,"amount":216000000,"amplitude":0.2043,"askPrice":23.6,"askSize":162,"bidPrice":23.59,"bidSize":73,"shortable":0,"etf":0,"ttmEps":0.3673,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793669400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.15,"symbolType":"stock","openAndCloseTimeList":[[1793583000000,1793590200000],[1793595600000,1793602800000]],"highLimit":23.27,"lowLimit":19.04,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":102891887,"isCdr":false,"pbRate":2.11,"roa":"--","peRate":64.252655,"roe":"2.13%","epsLYR":0.5048,"committee":-0.005128,"marketValue":2428000000,"turnoverRate":0.0911,"status":0,"floatMarketCap":2414000000},"requestUrl":"/m/hq/s/301331/tweets","defaultTab":"tweets","newsList":[{"id":"2678511595","title":"股市必读：恩威医药新发布《2026年三季度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678511595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678511595?lang=zh_cn&edition=full","pubTime":"2026-10-27 03:15","pubTimestamp":1793042111,"startTime":"0","endTime":"0","summary":"公司公告汇总2026年三季度报告2026年第三季度营业收入为190,745,896.54元，同比增长1.66%；归属于上市公司股东的净利润为6,400,956.18元，同比增长463.79%。上海荣正企业咨询服务（集团）股份有限公司关于恩威医药股份有限公司2023年限制性股票激励计划第三期归属条件成就相关事项之独立财务顾问报告2026年10月23日召开第三届董事会第十四次会议，审议通过2023年限制性股票激励计划第三期归属条件成就的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700004355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678877581","title":"恩威医药(301331)9月30日股东户数0.78万户，较上期增加16.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678877581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678877581?lang=zh_cn&edition=full","pubTime":"2026-10-25 17:17","pubTimestamp":1792919864,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩威医药披露，截至2026年9月30日公司股东户数为7822.0户，较6月30日增加1108.0户，增幅为16.5%。在中药行业个股中，恩威医药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.28万户。从股价来看，2026年6月30日至2026年9月30日，恩威医药区间跌幅为0.73%，在此期间股东户数增加1108.0户，增幅为16.5%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678187650","title":"图解恩威医药三季报：第三季度单季净利润同比增长463.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678187650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678187650?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:36","pubTimestamp":1792917377,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药2026年三季报显示，前三季度公司主营收入5.65亿元，同比下降11.23%；归母净利润2242.38万元，同比下降38.71%；扣非净利润1565.52万元，同比下降50.88%；其中2026年第三季度，公司单季度主营收入1.91亿元，同比上升1.66%；单季度归母净利润640.1万元，同比上升463.79%；单季度扣非净利润485.29万元，同比上升242.57%；负债率28.41%，投资收益259.88万元，财务费用33.22万元，毛利率49.76%。财报数据概要请见下图:本文数据来源于恩威医药2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675811323","title":"恩威医药（301331）披露控股股东一致行动人部分股份质押公告，10月14日股价下跌2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675811323","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675811323?lang=zh_cn&edition=full","pubTime":"2026-10-14 22:47","pubTimestamp":1791989233,"startTime":"0","endTime":"0","summary":"截至2026年10月14日收盘，恩威医药报收于21.05元，较前一交易日下跌2.32%，最新总市值为21.66亿元。该股当日开盘21.55元，最高21.64元，最低21.02元，成交额达2195.75万元，换手率为1.01%。恩威医药于2026年10月14日披露《关于控股股东一致行动人部分股份质押的公告》。公告显示，控股股东一致行动人成都泽洪、昌都市杰威特分别质押1,150,000股和1,350,000股，合计2,500,000股，占公司总股本2.43%。本次质押后，控股股东及其一致行动人累计质押股份占其所持股份比例为77.82%，占公司总股本50.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400040354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037096","title":"股市必读：恩威医药中报 - 第二季度单季净利润同比下降84.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037096","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037096?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:35","pubTimestamp":1787880903,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润351.81万元，同比下降84.04%。业绩披露要点财务报告2026年中报显示，上半年主营收入3.75亿元，同比下降16.62%；归母净利润1602.29万元，同比下降58.21%；扣非净利润1080.23万元，同比下降69.38%；第二季度单季度主营收入1.99亿元，同比下降21.16%；单季度归母净利润351.81万元，同比下降84.04%；单季度扣非净利润10.65万元，同比下降99.48%；负债率28.92%，投资收益193.05万元，财务费用54.65万元，毛利率51.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800017304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749948","title":"图解恩威医药中报：第二季度单季净利润同比下降84.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749948","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749948?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:41","pubTimestamp":1787769691,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药2026年中报显示，上半年度公司主营收入3.75亿元，同比下降16.62%；归母净利润1602.29万元，同比下降58.21%；扣非净利润1080.23万元，同比下降69.38%；其中2026年第二季度，公司单季度主营收入1.99亿元，同比下降21.16%；单季度归母净利润351.81万元，同比下降84.04%；单季度扣非净利润10.65万元，同比下降99.48%；负债率28.92%，投资收益193.05万元，财务费用54.65万元，毛利率51.18%。财报数据概要请见下图:本文数据来源于恩威医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700007077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662398748","title":"恩威医药（301331）披露2026年半年度募集资金存放与使用情况的专项报告，8月26日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662398748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662398748?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:48","pubTimestamp":1787755701,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，恩威医药报收于22.05元，较前一交易日下跌1.25%，最新总市值为22.69亿元。该股当日开盘22.33元，最高22.6元，最低21.9元，成交额达3830.53万元，换手率为1.68%。近日，恩威医药股份有限公司董事会发布2026年半年度募集资金存放与使用情况专项报告。募集资金总额522,692,000.00元，扣除发行费用后实际募集资金净额442,950,349.21元，已于2022年9月13日到账。截至2026年6月30日，累计投入募集资金项目296,282,762.65元，募集资金余额及现金管理产品本息合计144,885,444.38元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600053980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655700805","title":"恩威医药（301331）披露与专业投资机构共同投资设立基金进展公告，7月30日股价下跌4.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655700805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655700805?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:28","pubTimestamp":1785421698,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，恩威医药报收于19.35元，较前一交易日下跌4.02%，最新总市值为19.91亿元。该股当日开盘19.87元，最高20.15元，最低19.11元，成交额达6140.08万元，换手率为3.05%。恩威医药于2026年7月30日披露《关于与专业投资机构共同投资设立基金的进展公告》。公告显示，公司作为有限合伙人，以自有资金2000万元出资参与投资上海比邻星四期创业投资合伙企业，认缴出资比例由6.45%变更为4.808%。公司已于2026年5月和7月分别披露相关投资及增资进展公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652894972","title":"恩威医药（301331）披露控股股东部分股份解除司法冻结公告，7月17日股价下跌7.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652894972","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652894972?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:36","pubTimestamp":1784298976,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，恩威医药报收于21.06元，较前一交易日下跌7.51%，最新总市值为21.67亿元。该股当日开盘22.62元，最高22.73元，最低20.9元，成交额达5421.35万元，换手率为2.45%。恩威医药股份有限公司于2026年7月17日发布公告，公司控股股东成都恩威投资（集团）有限公司持有的137,584股股份已于2026年7月16日解除司法冻结，占其所持股份比例0.53%，占公司总股本比例0.13%。该事项不会导致公司控制权变更，亦不会对公司生产经营和公司治理产生重大不利影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700045086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651252480","title":"恩威医药：公司出资2000万元认购嘉兴磐霖嘉颐份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2651252480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651252480?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:03","pubTimestamp":1784077390,"startTime":"0","endTime":"0","summary":"公司作为有限合伙人以自有资金人民币2,000万元出资认购了嘉兴磐霖嘉颐创业投资合伙企业份额，出资占比9.9502%。详见公司于2025年11月14日发布的《关于与专业投资机构共同投资设立基金的公告》经向嘉兴磐霖嘉颐问询确认：上述信息均属实，上述4个投资项目已于2025年12月至2026年3月期间陆续完成交割。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500009902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651179904","title":"恩威医药（301331）披露控股股东及持股5%以上股东部分股份质押公告，7月14日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651179904","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651179904?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:32","pubTimestamp":1784021538,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，恩威医药报收于21.02元，较前一交易日上涨2.94%，最新总市值为21.63亿元。公告显示，控股股东恩威集团、持股5%以上股东成都杰威、成都泽洪将其持有的部分公司股份进行质押。质押用途均为自身生产经营，质押起始日为2026年7月9日，到期日为申请解除质押登记日。本次质押后，上述股东及其一致行动人合计质押股份占其所持公司股份的74.95%，占公司总股本的48.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400033922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649862701","title":"恩威医药（301331）披露与专业投资机构共同投资设立基金进展公告，7月6日股价下跌2.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649862701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649862701?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:43","pubTimestamp":1783348992,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，恩威医药报收于22.86元，较前一交易日下跌2.97%，最新总市值为23.52亿元。该股当日开盘23.54元，最高23.78元，最低22.8元，成交额达4309.66万元，换手率为1.81%。恩威医药于近日披露《关于与专业投资机构共同投资设立基金的进展公告》。公告显示，公司作为有限合伙人，以自有资金2000万元参与投资上海比邻星四期创业投资合伙企业，出资额不变，认缴出资比例由6.45%变更为4.808%。新增有限合伙人长三角创业投资引导基金认缴出资10,390万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600037834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647024378","title":"恩威医药（301331）披露控股股东部分股份解除质押公告，6月29日股价上涨4.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647024378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647024378?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:14","pubTimestamp":1782728092,"startTime":"0","endTime":"0","summary":"恩威医药股份有限公司于近日披露《关于控股股东部分股份解除质押的公告》。公告显示，公司控股股东成都恩威投资（集团）有限公司于2026年6月25日解除质押股份1,880,000股，占其所持股份比例7.31%，占公司总股本比例1.83%，质权人为万向信托股份公司。截至公告披露日，恩威集团累计质押股份21,040,000股，占其所持股份81.76%。公司称上述质押股份不存在平仓风险，不会对公司生产经营、公司治理产生实质性影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900029681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640195333","title":"恩威医药（301331）披露控股股东及持股5%以上股东部分股份解除质押公告，6月1日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640195333","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640195333?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:19","pubTimestamp":1780309168,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，恩威医药报收于25.06元，较前一交易日上涨1.75%，最新总市值为25.78亿元。公告显示，公司控股股东恩威集团及持股5%以上股东成都杰威近期办理了部分股份解除质押业务。恩威集团解除质押1,670,000股，占其所持股份比例6.49%，占公司总股本1.62%；成都杰威解除质押3,000,000股，占其所持股份比例21.27%，占公司总股本2.92%。截至公告日，恩威集团累计质押22,920,000股，占其持股89.07%；成都杰威累计质押7,200,000股，占其持股51.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638573518","title":"恩威医药：公司以2000万元出资认购嘉兴磐霖嘉颐创业投资合伙企业份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2638573518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638573518?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:36","pubTimestamp":1779853014,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药05月26日在投资者关系平台上答复投资者关心的问题。2025年 11月14日公司发布了《关于与专业投资机构共同投资设立基金的公告》，公司作为有限合伙人以自有资金人民币 2,000 万元出资认购嘉兴磐霖嘉颐创业投资合伙企业份额，出资占9.9502%。根据企查查等公开资料显示，嘉兴磐霖嘉颐创业投资合伙企业持有四川沃飞长空科技股份有限公司股份，持股比例为 0.5310%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637382890","title":"恩威医药（301331）披露2025年度持续督导定期现场检查报告，5月21日股价下跌3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637382890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637382890?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:17","pubTimestamp":1779358634,"startTime":"0","endTime":"0","summary":"近日，恩威医药披露《中信证券股份有限公司关于恩威医药股份有限公司2025年度持续督导定期现场检查报告》。公告显示，中信证券作为保荐机构，对恩威医药2025年度持续督导工作进行了现场检查，检查期间为2025年1月1日至2025年12月31日，现场检查时间为2026年5月7日。检查内容涵盖公司治理、内部控制、信息披露、募集资金使用、关联交易、对外担保、业绩情况、承诺履行及其他重要事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636701837","title":"恩威医药（301331）披露2025年年度股东会决议公告，5月19日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636701837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636701837?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:23","pubTimestamp":1779186195,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，恩威医药报收于26.59元，较前一交易日上涨0.68%，最新总市值为27.36亿元。恩威医药于近日披露《2025年年度股东会决议公告》。公告显示，公司于2026年5月18日召开2025年年度股东会，会议由董事会召集，董事长薛永江主持，采用现场与网络投票结合方式召开。出席会议股东及代理人共39人，代表股份64,536,259股，占公司有表决权股份总数的63.3481%。所有议案均获表决通过，无否决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900035358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083971","title":"恩威医药（301331）披露首次公开发行股票持续督导保荐总结报告书，5月15日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635083971?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:14","pubTimestamp":1778840060,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，恩威医药报收于26.45元，较前一交易日下跌0.68%，最新总市值为27.21亿元。公告显示，中信证券作为保荐机构，对恩威医药首次公开发行股票并在创业板上市后的持续督导工作进行总结。恩威医药于2022年9月21日在深交所创业板上市，股票代码301331.SZ，首次公开发行人民币普通股1754万股，募集资金净额4.43亿元，已按规定存放与使用，未发现违规情形。保荐机构将继续对募集资金使用履行督导义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500035271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710646","title":"恩威医药：公司一贯重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635710646?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:51","pubTimestamp":1778763102,"startTime":"0","endTime":"0","summary":"感谢您对公司的关注，公司未来是否进行回购股份操作需要视具体情况而定。公司一贯重视市值管理工作，以抓好经营管理、不断提升企业内在价值为根本，同时通过积极分红回报投资者、回购公司股份、股东增持等多种途径提升投资者的投资体验，吸引包括机构投资者在内的更多投资者关注、投资本公司。未来公司将进一步加强与投资者沟通，实现公司价值的传递，保持与资本市场的良好互动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400040826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223204","title":"恩威医药：2025-2027三年发展及增长计划，总目标是“三年番一翻”","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223204","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635223204?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:48","pubTimestamp":1778662092,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药05月13日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300030063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793623664902,"stockEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0522},{"period":"6month","weight":-0.2005},{"period":"1year","weight":-0.2628},{"period":"ytd","weight":-0.1699}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"恩威医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7822人(较上一季度增加16.50%)","perCapita":"13075股","listingDate":"2022-09-21","address":"西藏自治区昌都市卡若区经开区A坝区创业大道恩威大厦","registeredCapital":"10289万元","survey":" 恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是妇科外用洗液“洁尔阴洗液”、软膏、栓剂、胶囊剂、泡腾片。","listedPrice":29.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩威医药,301331,恩威医药股票,恩威医药股票老虎,恩威医药股票老虎国际,恩威医药行情,恩威医药股票行情,恩威医药股价,恩威医药股市,恩威医药股票价格,恩威医药股票交易,恩威医药股票购买,恩威医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}